Literature DB >> 6970206

Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.

B F Haynes, P Bunn, D Mann, C Thomas, G S Eisenbarth, J Minna, A S Fauci.   

Abstract

Using a panel of monoclonal antibodies and rabbit heteroantisera, we have studied the cell surface markers of peripheral blood (PB) Sezary cells from six patients with mycosis fungoides or Sezary syndrome, disease grouped within the spectrum of cutaneous T cell lymphomas (CTCL). Furthermore, we have studied two cell lines (Hut 78 and Hut 102) derived from malignant Sezary T cells from CTCL patients. The monoclonal antibody 3A1 defines a major human PB T cell subset (85% of PB T cells) while the antigen defined by the monoclonal antibody 4F2 is present on a subset (70%) of activated PB T cells and on circulating PB monocytes. In contrast to normal subjects in whom 60-70% of circulating PB mononuclear cells were 3A1(+) T cells, PB mononuclear cells from six CTCL patients studied had an average of only 10.6+/-3.2% 3A1(+) T cells. Whereas 85% of E-rosette positive cells from normal individuals were 3A1(+), virtually all E-rosette positive T cells from the Sezary patients were 3A1(-). Two patients with high numbers of circulating Sezary T cells had both aneuploid and diploid PB T cell populations present; after separation of PB T cells into 3A1(+) and 3A1(-) cell suspensions, all 3A1(-) cells were found to be aneuploid. In contrast to normal resting PB T cells which were 4F2(-), all PB Sezary cells were 4F2(+), suggesting a state of activation. The 3A1 antigen was on a variety of acute lymphoblastic leukemia T cell lines (HSB-2, RPMI-8402, MOLT4, CEM) but was absent on the Hut 78 and Hut 102 Sezary T cell lines. Using rabbit anti-human T and anti-human Ia (p23, 30) antisera, we found that all malignant Sezary PB cells tested were killed by anti-T cell antiserum plus complement but not by anti-Ia plus complement. In contrast, Sezary cell lines Hut 78 and 102, were killed by both anti-T cell antiserum and anti-Ia plus complement. Similar to 3A1(-) normal PB T cells, 3A1(-) Sezary PB T cells proliferated poorly to phytohemagglutinin and concanavalin A. However, 3A1(-) Sezary T cells were able to provide T cell help towards pokeweed mitogen-induced in vitro B cell immunoglobulin synthesis, an immunoregulatory function limited to 3A1(+) T cells in normal subjects.Thus, the 3A1 antigen is present on 85% of normal PB T cells, and on most T-acute lymphoblastic leukemia lines tested; in contrast the 3A1 antigen is not present on the majority of circulating malignant Sezary PB T cells nor on T cell lines derived from malignant Sezary T cells. The lack of expression of the 3A1 antigen may be associated with malignant transformation of T cells in CTCL and may be an important marker for tracing the clonal origin of the malignant Sezary T cell.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6970206      PMCID: PMC370595          DOI: 10.1172/JCI110062

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.

Authors:  T Yoshida; R Edelson; S Cohen; I Green
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

2.  Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders.

Authors:  M Lutzner; R Edelson; P Schein; I Green; C Kirkpatrick; A Ahmed
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

3.  Detection and partial characterization of human T and B lymphocyte membrane antigens with antisera to HSB and SB cell lines.

Authors:  J K Anderson; R S Metzgar
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

4.  Fluorescence activated cell sorting.

Authors:  W A Bonner; H R Hulett; R G Sweet; L A Herzenberg
Journal:  Rev Sci Instrum       Date:  1972-03       Impact factor: 1.523

5.  Definition of a continuous human cell line derived from neuroblastoma.

Authors:  J J Tumilowicz; W W Nichols; J J Cholon; A E Greene
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

6.  Terminal deoxynucleotidyl transferase activity in malignant lymphomas.

Authors:  J A Donlon; E S Jaffe; R C Braylan
Journal:  N Engl J Med       Date:  1977-09-01       Impact factor: 91.245

7.  Distribution of Ia-like molecules on the surface of normal and leukemic human cells.

Authors:  S F Schlossman; L Chess; R E Humphreys; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

8.  Lack of effector cell function in chronic lymphocytic leukemia, a B-cell malignancy, and the Sézary syndrome, a T-cell malignancy.

Authors:  A V Muchmore; R M Blaese; L C Altman
Journal:  Clin Immunol Immunopathol       Date:  1978-07

9.  The Sézary syndrome: a malignant proliferation of helper T cells.

Authors:  S Broder; R L Edelson; M A Lutzner; D L Nelson; R P MacDermott; M E Durm; C K Goldman; B D Meade; T A Waldmann
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539

View more
  12 in total

1.  Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.

Authors:  Melissa A Byers; Psachal A Calloway; Laurie Shannon; Heather D Cunningham; Sarah Smith; Fang Li; Brian C Fassold; Charlotte M Vines
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

2.  The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.

Authors:  Michael J Kelly-Sell; Youn H Kim; Suzanne Straus; Bernice Benoit; Cameron Harrison; Katherine Sutherland; Randall Armstrong; Wen-Kai Weng; Louise C Showe; Maria Wysocka; Alain H Rook
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

3.  Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.

Authors:  Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook
Journal:  Leuk Lymphoma       Date:  2011-10

4.  Sézary T-cell activating factor is a Chlamydia pneumoniae-associated protein.

Authors:  J T Abrams; E C Vonderheid; S Kolbe; D M Appelt; E J Arking; B J Balin
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

5.  Analysis of helper activity on pokeweed mitogen- and interleukin 2-driven immunoglobulin synthesis by neoplastic T4+ cells.

Authors:  F Miedema; J W van Oostveen; F G Terpstra; A W van den Wall Bake; R Willemze; E A Rauws; R Bieger; M B van 't Veer; D Catovsky; C J Melief
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

6.  Lymphocyte phenotype and function in pseudolymphoma associated with Sjögren's syndrome.

Authors:  R I Fox; T C Adamson; S Fong; C A Robinson; E L Morgan; J A Robb; F V Howell
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

Review 7.  CD98 at the crossroads of adaptive immunity and cancer.

Authors:  Joseph M Cantor; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2012-04-12       Impact factor: 5.285

8.  Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma.

Authors:  B N Lee; M Duvic; C K Tang; C Bueso-Ramos; Z Estrov; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

9.  T gamma lymphocytosis is clinically non-progressive but immunologically heterogeneous.

Authors:  F Miedema; F G Terpstra; J W Smit; J P van der Veen; C J Melief
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

10.  Functional and phenotypic studies of Japanese adult T cell leukemia cells.

Authors:  C Morimoto; T Matsuyama; C Oshige; H Tanaka; T Hercend; E L Reinherz; S F Schlossman
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.